Document is current
Any future updates will be listed below
-
Authors
Foss, Dana V. https://orcid.org/0000-0003-2937-4703
Muldoon, Joseph J. https://orcid.org/0000-0003-3784-3565
Nguyen, David N. https://orcid.org/0000-0001-6808-2717
Carr, Daniel
Sahu, Srishti U. https://orcid.org/0000-0002-4950-1557
Hunsinger, John M.
Wyman, Stacia K. https://orcid.org/0000-0002-8937-8397
Krishnappa, Netravathi
Mendonsa, Rima
Schanzer, Elaine V. https://orcid.org/0000-0003-2863-100X
Shy, Brian R. https://orcid.org/0000-0001-9569-3708
Vykunta, Vivasvan S. https://orcid.org/0000-0002-5409-8635
Allain, Vincent
Li, Zhongmei
Marson, Alexander https://orcid.org/0000-0002-2734-5776
Eyquem, Justin https://orcid.org/0000-0001-8262-1190
Wilson, Ross C. https://orcid.org/0000-0002-0644-5540
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research (201811MFE-415820-284975)
Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (201811MFE-415820-284975)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (L40AI140341, K08AI153767, UG3AI150552, UG3AI150552)
- License Information
-
More Information
Article History
Received: 24 January 2022
Accepted: 26 March 2023
First Online: 25 April 2023
Competing interests
: D.V.F., D.N.N., D.C., S.U.S., J.M.H., A.M. and R.C.W. are named inventors on a patent application related to this work. D.N.N. is a holder of patents pertaining to but not resulting from this work. D.N.N. is a consultant for and owns stock in Navan Technologies. B.R.S. and A.M. are holders of patents pertaining to but not resulting from this work. J.E. is a compensated co-founder at Mnemo Therapeutics, a compensated scientific advisor to Cytovia Therapeutics, owns stocks in Mnemo Therapeutics and Cytovia Therapeutics, is a compensated member of the scientific advisory board at Treefrog Therapeutics, and has received a consulting fee from Casdin Capital. The J.E. laboratory has received research support from Cytovia Therapeutics, Mnemo Therapeutics and Takeda. J.E. is a holder of patents pertaining to but not resulting from this work. A.M. is a co-founder of Arsenal Biosciences, Spotlight Therapeutics and Survey Genomics, serves on the boards of directors at Spotlight Therapeutics and Survey Genomics, is a board observer (and former member of the board of directors) at Arsenal Biosciences, is a member of the scientific advisory boards of Arsenal Biosciences, Spotlight Therapeutics, Survey Genomics, NewLimit and Amgen, owns stock in Arsenal Biosciences, Spotlight Therapeutics, NewLimit, Survey Genomics and PACT Pharma, and has received fees from Arsenal Biosciences, Spotlight Therapeutics, NewLimit, 23andMe, PACT Pharma, Juno Therapeutics, Trizell, Vertex, Merck, Amgen, Genentech, AlphaSights, Rupert Case Management, Bernstein and ALDA. A.M. is an investor in and informal advisor to Offline Ventures and a client of EPIQ. The A.M. laboratory has received research support from Juno Therapeutics, Epinomics, Sanofi, GlaxoSmithKline, Gilead and Anthem. The R.C.W. laboratory has received research support from Genentech, Roche and Pfizer; the associated research is distinct from what is reported here.
